Skip to main content

Table 3 Selected comorbidities during the 5 years prior to ATTRv amyloidosis diagnosis

From: The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

  Newly diagnosed ATTRv amyloidosis patients
N = 141
Matched controlsa
N = 423
P value Newly diagnosed ATTRv amyloidosis patients
N = 141
Matched controlsa
N = 423
P value Newly diagnosed ATTRv amyloidosis patients
N = 141
Matched controlsa
N = 423
P value Newly diagnosed ATTRv amyloidosis patients
N = 141
Matched controlsa
N = 423
P value
  Ocular, and severe organ dysfunction or failure
  Glaucoma Vitreous opacity Renal failure Organ transplant
N (%) 21 (14.9) 53 (12.5) 0.471 12 (8.5) 18 (4.3) 0.051 28 (19.9) 24 (5.7) < 0.001 4 (2.8) 0 (0.0) < 0.001
First evidence occurred, n (%)    0.285    0.208    < 0.001    0.007
 No evidence 120 (85.1) 370 (87.5)   129 (91.5) 405 (95.7)   113 (80.1) 399 (94.3)   137 (97.2) 423 (100.0)  
 Pre Y1 1 (0.7) 0 (0)   2 (1.4) 3 (0.7)   13 (9.2) 4 (0.9)   2 (1.4) 0 (0)  
 Pre Y2 1 (0.7) 1 (0.2)   2 (1.4) 4 (0.9)   6 (4.3) 6 (1.4)   1 (0.7) 0 (0)  
 Pre Y3 3 (2.1) 9 (2.1)   4 (2.8) 2 (0.5)   2 (1.4) 3 (0.7)   0 (0) 0 (0)  
 Pre Y4 1 (0.7) 10 (2.4)   2 (1.4) 3 (0.7)   2 (1.4) 3 (0.7)   1 (0.7) 0 (0)  
 Pre Y5 15 (10.6) 33 (7.8)   2 (1.4) 6 (1.4)   5 (3.5) 8 (1.9)   0 (0) 0 (0)  
  Gastrointestinal    
  Diarrhea Constipation Nausea/vomiting Weight loss
N (%) 25 (17.7) 47 (11.1) 0.041 35 (24.8) 49 (11.6) < 0.001 38 (27.0) 55 (13.0) < 0.001 19 (13.5) 30 (7.1) 0.020
First evidence occurred, n (%)    0.352    0.005    < 0.001    0.003
 No evidence 116 (82.3) 376 (88.9)   106 (75.2) 374 (88.4)   103 (73.0) 368 (87.0)   122 (86.5) 393 (92.9)  
 Pre Y1 5 (3.5) 8 (1.9)   11 (7.8) 11 (2.6)   6 (4.3) 5 (1.2)   10 (7.1) 5 (1.2)  
 Pre Y2 4 (2.8) 11 (2.6)   9 (6.4) 14 (3.3)   4 (2.8) 15 (3.5)   0 (0) 7 (1.7)  
 Pre Y3 6 (4.3) 11 (2.6)   5 (3.5) 5 (1.2)   8 (5.7) 17 (4.0)   3 (2.1) 6 (1.4)  
 Pre Y4 5 (3.5) 6 (1.4)   5 (3.5) 11 (2.6)   9 (6.4) 8 (1.9)   2 (1.4) 6 (1.4)  
 Pre Y5 5 (3.5) 11 (2.6)   5 (3.5) 8 (1.9)   11 (7.8) 10 (2.4)   4 (2.8) 6 (1.4)  
  Musculoskeletal and cardiovascular    
  Spinal stenosis Carpal tunnel Congestive heart failure Hypotension
N (%) 23 (16.3) 43 (10.2) 0.049 13 (9.2) 28 (6.6) 0.030 33 (23.4) 25 (5.9) < 0.001 26 (18.4) 26 (6.1) < 0.001
First evidence occurred, n (%)    0.012    0.104    < 0.001    < 0.001
 No evidence 118 (83.7) 380 (89.8)   128 (90.8) 395 (93.4)   108 (76.6) 398 (94.1)   115 (81.6) 397 (93.9)  
 Pre Y1 3 (2.1) 16 (3.8)   4 (2.8) 4 (0.9)   11 (7.8) 6 (1.4)   11 (7.8) 6 (1.4)  
 Pre Y2 5 (3.5) 6 (1.4)   2 (1.4) 6 (1.4)   6 (4.3) 3 (0.7)   5 (3.5) 6 (1.4)  
 Pre Y3 3 (2.1) 6 (1.4)   3 (2.1) 2 (0.5)   7 (5.0) 3 (0.7)   3 (2.1) 5 (1.2)  
 Pre Y4 2 (1.4) 8 (1.9)   4 (2.8) 8 (1.9)   6 (4.3) 4 (0.9)   2 (1.4) 4 (0.9)  
 Pre Y5 10 (7.1) 7 (1.7)   0 (0) 8 (1.9)   3 (2.1) 9 (2.1)   5 (3.5) 5 (1.2)  
  Cardiovascular (continued)    
  Dyspnea Ventricular hypertrophy Hypertrophic cardiomyopathy Restrictive cardiomyopathy
N (%) 70 (49.6) 109 (25.8) < 0.001 28 (19.9) 24 (5.7) < 0.001 8 (5.7) 2 (0.5) < 0.001 11 (7.8) 8 (1.9) < 0.001
First evidence occurred, n (%)    < 0.001    < 0.001    0.003    < 0.001
 No evidence 71 (50.4) 314 (74.2)   113 (80.1) 399 (94.3)   133 (94.3) 421 (99.5)   130 (92.2) 415 (98.1)  
 Pre Y1 9 (6.4) 15 (3.5)   8 (5.7) 6 (1.4)   3 (2.1) 1 (0.2)   1 (0.7) 0 (0)  
 Pre Y2 12 (8.5) 15 (3.5)   6 (4.3) 6 (1.4)   2 (1.4) 0 (0)   4 (2.8) 0 (0)  
 Pre Y3 9 (6.4) 21 (5.0)   5 (3.5) 6 (1.4)   1 (0.7) 1 (0.2)   1 (0.7) 2 (0.5)  
 Pre Y4 15 (10.6) 16 (3.8)   4 (2.8) 1 (0.2)   1 (0.7) 0 (0)   3 (2.1) 0 (0)  
 Pre Y5 25 (17.7) 42 (9.9)   5 (3.5) 5 (1.2)   1 (0.7) 0 (0)   2 (1.4) 6 (1.4)  
  Nervous system and metabolic   
  Neuropathy Incontinence Diabetes
N (%) 37 (26.2) 25 (5.9) < 0.001 20 (14.2) 23 (5.4) < 0.001 56 (39.7) 107 (25.3) 0.001
First evidence occurred, n (%)    < 0.001    0.005    0.022
 No evidence 104 (73.8) 398 (94.1)   121 (85.8) 400 (94.6)   85 (60.3) 316 (74.7)  
 Pre Y1 17 (12.1) 7 (1.7)   2 (1.4) 2 (0.5)   4 (2.8) 8 (1.9)  
 Pre Y2 7 (5.0) 4 (0.9)   1 (0.7) 4 (0.9)   6 (4.3) 12 (2.8)  
 Pre Y3 6 (4.3) 4 (0.9)   5 (3.5) 2 (0.5)   4 (2.8) 3 (0.7)  
 Pre Y4 1 (0.7) 3 (0.7)   6 (4.3) 7 (1.7)   10 (7.1) 16 (3.8)  
 Pre Y5 6 (4.3) 7 (1.7)   6 (4.3) 8 (1.9)   32 (22.7) 68 (16.1)  
  1. ATTRv hereditary transthyretin
  2. aMatched with age, gender, and region